Abstract
We study the transition of an epidemic from growth phase to decay of the active infections in a population when lockdown measures are introduced to reduce the probability of disease transmission. While in the case of uniform lockdown a simple compartmental model would indicate instantaneous transition to decay of the epidemic, this is not the case when partially isolated active clusters remain with the potential to create a series of small outbreaks. We model this using a connected set of stochastic susceptible-infected-removed/recovered (SIR) models representing the locked-down majority population (where the reproduction number is less than one) weakly coupled to a large set of small clusters where the infection may propagate. We find that the presence of such active clusters can lead to slower than expected decay of the epidemic and significantly delayed onset of the decay phase. We study the relative contributions of these changes to the additional total infections caused by the active clusters within the locked-down population. We also demonstrate that limiting the size of the inevitable active clusters can be efficient in reducing their impact on the overall size of the epidemic outbreak.
Statement of Significance Restricting movement and interaction of individuals has been widely used in trying to limit the spread of COVID-19, however, there is limited understanding of the efficiency of these measures as it is difficult to predict how and when they lead to the decay of an epidemic. In this article, we develop a mathematical framework to investigate the transition to the decay phase of the epidemic taking into account that after lockdown a large number of active groups remain with the potential to produce localised outbreaks affecting the overall decay of infections in the population. Better understanding of the mechanism of transition to the decay of the epidemic can contribute to improving the implementation of public health control strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This work is a mathematical model.
